一分钟看懂
这是一项关于晚期或转移性恶性实体瘤的II 期研究，登记的药物或干预包括Laboratory Biomarker Analysis；Pembrolizumab；Questionnaire Administration，当前状态为研究进行中，已停止招募。登记地点显示中国Houston有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Laboratory Biomarker Analysis；Pembrolizumab；Questionnaire Administration · II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- M D Anderson Cancer Center · Houston
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Be willing and able to provide written informed consent/assent for the trial
- * Have measurable disease based on RECIST 1.1 or irRECIST; only cohort 9 and 10 can have evaluable disease (non-measurable lesions); tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions; patients may have bone metastatic disease evaluable according to tumor evaluation criteria best suitable and accepted for the tumor type evaluated
- * Have one of the following advanced (unresectable and/or metastatic) solid tumor indications that has progressed following standard therapies, where standard therapies are available:
- Squamous cell carcinoma of the skin
- Small cell malignancies of non-pulmonary origin
- Adrenocortical carcinoma
- Medullary renal cell carcinoma
- Carcinoma of unknown primary
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT02721732；登记信息更新于 2026-07-17；本站同步于 2026-10-08。